Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;11(6):781-91.
doi: 10.2217/pgs.10.49.

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

Affiliations

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

Stuart A Scott et al. Pharmacogenomics. 2010 Jun.

Abstract

Aims: CYP4F2*3 (p.V433M) has been associated with higher warfarin dose requirements; however, its frequency, like other CYP2C9 and VKORC1 variants, has not been systematically assessed in major racial/ethnic populations. Thus, we determined the individual and combined frequencies of important CYP2C9, VKORC1 and CYP4F2 variants in several racial/ethnic groups.

Materials & methods: Healthy African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish (AJ) blood donors were genotyped for CYP2C9 (*2, *3, *4, *5, *6, *8, *11 and *13), VKORC1 (g.-1639G>A) and CYP4F2 (*3 [p.V433M] and rs2189784).

Results: The combined frequencies of variant CYP2C9 alleles were 0.133, 0.078, 0.212, 0.178 and 0.212 among African-American, Asian, Caucasian, Hispanic and AJ individuals, respectively. CYP4F2*3 frequencies were prevalent (0.233-0.342) among Asian, Caucasian, Hispanic and AJ individuals, while significantly less frequent among African-Americans (0.117; p < 0.0001). In addition, CYP4F2*3 was in linkage disequilibrium with rs2189784, an allele recently associated with time-to-therapeutic international normalized ratio, among all studied populations. Importantly, 87-95% of Asian, Caucasian, Hispanic and AJ individuals had a variant CYP2C9, VKORC1 and/or CYP4F2*3 allele, compared with only 53% of African-Americans (p < 0.0001).

Conclusions: Compared with other racial/ethnic populations studied, only approximately one in 80 African-Americans were CYP4F2*3 homozygous, indicating that this population would benefit less from dosing algorithms that include this variant. In addition, the unique allele frequency profiles identified among the different populations partly explain why genotype-guided warfarin dosing algorithms perform less well for African-Americans and suggest that other unidentified genetic and/or nongenetic factors that influence warfarin dosage may exist in this population.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Variant CYP2C9 (combined *2, *3, *5, *6, *8 and *11), VKORC1 (g.-1639G>A) and CYP4F2 (*3 [rs2108622] and rs2189784) allele frequencies in various racial and ethnic populations
Wild-type and variant allele frequencies are represented by dark blue and light blue shading, respectively.
Figure 2
Figure 2. CYP2C9, VKORC1 and CYP4F2 genotype frequency profiles in various racial and ethnic populations
CYP2C9, VKORC1 and CYP4F2 genotype frequencies were combined for a subset of subjects with available data. Frequencies were subdivided based on variant CYP2C9 (*2, *3, *5, *6, *8 and *11), VKORC1 (g.-1639G>A) and CYP4F2 (*3; p.V433M) alleles. For each population studied, the frequency of homozygosity for a WT genotype at all three loci is highlighted by a dark blue bar, and a dotted line indicates the frequency profile trend. Note the high frequency (47.5%) of African–Americans with WT alleles compared with those in all other studied populations (p < 0.0001). n: Number of subjects; vt: Variant allele; WT: Wild-type allele (CYP2C9: *1; VKORC1: g.-1639G; CYP4F2: p.V433).

Comment in

References

    1. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7(2):99–111. ■ Thorough overview of warfarin pharmacogenetics.

    1. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy. 2008;28(9):1084–1097. - PMC - PubMed
    1. Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics. 2008;9(9):1331–1346. ■ Excellent review on pharmacogenetic warfarin dosing algorithms.

    1. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl.):S8–S21. - PubMed
    1. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 2008;84(3):326–331. - PMC - PubMed

Publication types

MeSH terms